Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Phase i, randomized, open-label study evaluating the pharmacokinetics, pharmacodynamics and safety profile of repeated five-day-dose of intravenous rabeprazole sodium in healthy chinese volunteers

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Poster
  • By: WANG, Zhuo (Shanghai Changhai Hospital, SMMU, Department of Pharmacy, Shanghai, China)
  • Co-author(s): Gao, Shen (Shanghai Changhai Hospital, SMMU, Shanghai, China)
    Zhao, Na Ping (Shanghai Changhai Hospital, SMMU, Shanghai, China)
    Zhou, Jia (Shanghai Changhai Hospital, SMMU, Shanghai, China)
    Tang, Shi Xin (Shanghai Changhai Hospital, SMMU, Shanghai, China)
    Zhang, Yi Shan (Jiangsu Aosaikang Pharmaceutical Co., Ltd., Nanjing, China)
    Du, Yi Qi (Shanghai Changhai Hospital, SMMU, Shanghai, China)
    Li, Zhao Shen (Shanghai Changhai Hospital, SMMU, Shanghai, China)
    Kang, Xin (Shanghai Changhai Hospital, SMMU, Shanghai, China)
    Yang, Wu Yun (Shanghai Changhai Hospital, SMMU, Shanghai, China)
    Cai, Ting Ting (Shanghai Changhai Hospital, SMMU, Shanghai, China)
    Zhang, Li (Shanghai Changhai Hospital, SMMU, Shanghai, China)
  • Abstract:

    BACKGROUND: Rabeprazole sodium (Rab) is a new proton pump inhibitor. Several oral dosage forms of Rab have been approved. However, they may have low bioavailability and long onset time because Rab has obvious hepatic first-pass effect and is not stable in acidic media. Therefore dosage form for injection of Rab is necessary. However, the data of..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses